Company ProfilePremium

Avecho Biotechnology Limited

Company Profile Analysis

Ticker: AVE.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Avecho Biotechnology Limited - Company showcase

Year Founded & Workforce

1992

15 Employees

Avecho Biotechnology Limited logo

Avecho Biotechnology Limited Employee Contacts

3 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Avecho Biotechnology Limited Overview

Avecho is a Melbourne-based, clinical-stage specialty pharmaceutical micro-cap. It builds products on a proprietary, patented vitamin-E-derived excipient, Tocopheryl Phosphate Mixture (TPM®), which improves the solubility and the oral, dermal and transdermal absorption of drugs and nutrients. Its value now rests almost entirely on one asset: a TPM-enhanced cannabidiol (CBD) soft-gel capsule in a pivotal Phase III trial for insomnia. The trial is designed to support registration with Australia's TGA under the low-dose, over-the-counter (Schedule 3) CBD pathway. A 10-year exclusive Australian licence with Sandoz (US$3M upfront, up to US$16M in milestones, 14–19% royalties) validates the asset commercially. A positive interim analysis in June 2026, which continued the trial without increasing the sample size, materially de-risked it. Underneath sits a small legacy ingredients business, selling TPM® and Vital ET® to a concentrated customer base, which generates roughly A$0.5–1.2M a year. Avecho is therefore a binary, event-driven biotech, funded by equity, R&D tax refunds and licence income.


Company's own description [AR25, Principal activities].

Avecho describes itself as developing and commercialising innovative human and animal health products using TPM®. TPM is derived from vitamin E through proprietary, patented processes and enhances the solubility and the oral, dermal and transdermal absorption of drugs and nutrients. The company names its lead asset as a proprietary CBD TPM soft-gel capsule, shown to increase CBD absorption and now in Phase III development for insomnia.

Independent characterisation.

In practice, Avecho runs three economic engines of very different size and maturity.

  1. Clinical development (Human Health segment). This is where most capital goes and where most enterprise value sits. Spending is concentrated on the Phase III CBD-TPM insomnia program. Clinical development expenses were A$3.48M of the A$4.31M FY2025 R&D budget [AR25 Note 7]. The model is develop-and-license: Avecho runs the trial and the regulatory work, out-licenses commercial rights by territory, and keeps manufacturing and supply through third-party CMOs. Under the Sandoz agreement, Avecho will sell finished product to Sandoz and also receive royalties [AR25].

  2. Ingredient production (Production segment). Avecho has TPM® and Vital ET® made and sells them wholesale at a fixed price per kilogram. Vital ET® is a cosmetic/skin-care ingredient; TPM® serves as a drug-delivery excipient. Revenue is lumpy and highly concentrated: about 97% of FY2025 Production revenue came from a single external customer group (FY2024: 96%; FY2023: 85%; FY2022: 92%) [AR25; AR23]. The going-concern notes name Ashland and Themis as customers [AR25; AR23].

  3. Licensing and royalties (legacy). These are historical out-licences of TPM formulations. They include a 5% royalty on net sales of TPM-daptomycin from Mylan (now Viatris), set by the December 2018 settlement, and partner-funded programs such as Perrigo's TPM-ibuprofen gel and Arthur Group's oncology solubilisation work. Licence revenue has been immaterial: A$69,262 in FY2022 and nil since [AR23; AR25].

Revenue model mix (FY2025) [AR25 Note 5].

The Sandoz upfront payment (A$4,832,762) is held as a non-current contract liability. It is not yet revenue and will be recognised as performance obligations under the development and licensing agreement are satisfied [AR25 Note 15; HY26].

Non-operating funding stream. Australia's refundable R&D Tax Incentive (an 18.5% premium above the company tax rate for entities with turnover under A$20M) is structurally important:

  • FY2025 R&D tax incentive income: A$1,995,884, which exceeds product revenue [AR25].

  • The refund is typically pre-funded through R&D advance facilities from Endpoints Capital (15.8% interest on the FY2024 facility) [AR25 Note 13].

Value-chain position.

Avecho is an IP owner and integrator. It owns the excipient process patents and formulation know-how, outsources GMP manufacture (Procaps Group for the CBD soft-gels [AR23]; an Australian third-party GMP CMO for the ibuprofen gel [AR23]), and outsources clinical operations to Australian trial sites. It relies on partners such as Sandoz for distribution and commercialisation.

Customer types and end-markets.

Strategy

Stated strategic themes [AR25; ASX releases 2025–26]. The company's strategy rests on five themes, paraphrased from its own disclosures:

  1. Complete Phase III and file with the TGA. The trial is the company's final clinical step before a TGA submission to register the CBD-TPM capsule for insomnia.

  2. Be first to market in Australia's OTC CBD category. The company wants to be first through the TGA's unique Schedule 3 over-the-counter CBD pathway and estimates the market could exceed US$125M a year [ASX 2 Mar 2026; 21 May 2026].

  3. License territory by territory. Following the Sandoz deal, business development has broadened to other international markets, with "licensing discussions remain active across multiple jurisdictions" [AR25]. The interim result is said to strengthen the licensing position outside Australia [ASX 24 Jun 2026].

  4. Prepare manufacturing before the data. The A$2.5M placement funded registration batches for long-term stability, scale-up to commercial batch size, regulatory manufacturing documentation and capsules for the second Phase III cohort. The aim is to lodge with the TGA as soon as possible after a positive outcome [AR25].

  5. Engage global regulators. The company plans engagement with the US FDA and European authorities to define regional development paths [3P: Biotech Dispatch; Sleep Review].

Strategic initiatives in the last 24 months.

ESG and sustainability commitments. No formal ESG framework, emissions targets or sustainability report have been published. Disclosures are limited to environmental compliance on chemical waste [AR25].

Cost programs. None announced; the cost base is already minimal (about 15 staff).

Medium-term financial targets and guidance. No financial guidance or medium-term revenue or margin targets are provided. Operational guidance:

  • FY2025 report: interim analysis targeted for H1 2026. Delivered 24 Jun 2026.

  • AGM and interim deck: complete Phase III dosing to the final patient (H2 2026 trial continuation), then final analysis and TGA submission. Specific dates for top-line results and submission are not publicly disclosed.

Products & Services

Platform technology

ProductDescription and capabilitiesTarget customerStatus / yearPricing
TPM® (Tocopheryl Phosphate Mixture)Vitamin-E-derived mixture of tocopheryl phosphates made by a proprietary, patented process. Improves solubility and oral, dermal and transdermal absorption. Historically also branded "Targeted Penetration Matrix".Pharma and consumer-health formulators; Avecho's own pipelineCommercial excipient. US manufacturing-process patent allowed May 2023, running to at least Dec 2037Fixed price per kg; 50% deposit and 50% on delivery [AR25 Note 5]

Production segment (commercial)

ProductDescriptionCustomerStatusPricing / terms
Vital ET®TPM-based vitamin E ingredient for skin-care and cosmetic formulationsAshland (global speciality ingredients); single customer group about 97% of segment revenueCommercial; main source of FY2025 revenue ("revenue consisted mainly of Vital ET® sales")Fixed price per kg; 45-day terms [AR25]
TPM® bulk excipientExcipient supplied to licenseesThemis Medicare (India); Viatris/Mylan (exclusive TPM sourcing for TPM-daptomycin, per 2018 settlement)Commercial, small volumes. India revenue A$22,500 in FY2025Fixed price per kg

Human Health — lead clinical asset

ProductDescription and specificationsTargetStage / latestCommercial terms
CBD TPM® soft-gel capsule (insomnia)Oral cannabidiol in a TPM-enhanced soft-gel, shown to increase CBD absorption. Doses 75 mg and 150 mg nightly. Made by Procaps Group (US CMO); registration and commercial batches under way (FY2025 placement)Adults with insomnia. Initially Australian pharmacy OTC (Schedule 3) channel, then internationalPivotal Phase III, multi-centre, randomised, double-blind, placebo-controlled; target 519 participants; 8-week treatment. Positive interim analysis 24 Jun 2026; second cohort recruiting from 31 Aug 2026Australia licensed to Sandoz (10 yrs): US$3M upfront, up to US$16M development milestones, 14–19% tiered royalties, Avecho supplies product. Rest of world retained (Sandoz ROFR) [AR25]

Human Health — cannabinoid portfolio (secondary)

ProductDescriptionStatus
CBD TPM oral oilTPM-enhanced oral cannabinoid oilDeveloped; part of four-dosage-form portfolio [AR23]
TPM cannabinoid gummies (edibles)First-generation glycerin/gelatin chewables with TPM-enhanced cannabinoidsDevelopment completed Jun 2023; aimed at North American medicinal and recreational markets [AR23]
TPM topical cannabinoid gelDermal cannabinoid deliveryDeveloped [AR23]
CBD supplied to academic research (Lambert Initiative, University of Sydney)Avecho's oral CBD product used for novel indications not previously linked to CBDAvecho estimated its products would be used in seven clinical trials during 2023 [3P: SmallCaps 2023]

Human Health — partnered / legacy TPM formulations

ProductPartnerDescriptionStatus
TPM®-ibuprofen topical gelPerrigo Company plc (NYSE: PRGO)Topical NSAID gel for a US pain indication; Avecho manages Australian GMP manufacturePartner-funded development (2023 onward); current status not updated in FY2025 report
TPM-daptomycin injectableViatris (formerly Mylan)TPM-solubilised antibioticMylan holds full rights; 5% royalty on net sales and exclusive TPM supply (Dec 2018 settlement). No royalty revenue reported FY2022–FY2025
TPM®-phytonadione injection (vitamin K1)Athenex → (Sagent)Injectable; FDA pre-IND feedback said existing TPM toxicology appeared sufficientPartnership dissolved after Sagent bought Athenex injectables (Jun 2023) [AR23]
TPM-solubilised oncology drugsArthur Group (US)Optimised cancer drug solubilisation, work done at Arthur Group's US facilityLicence and development agreement May 2023 [AR23]
TPM/Oxycodone transdermal patch—Opioid patch for postherpetic neuralgia painLegacy (Phosphagenics era); early clinical work completed; not active in recent reports
TPM/Oxymorphone patch—Opioid transdermalLegacy; early clinical
Transdermal patch collaborationTerumoPatch delivery using TPMLegacy (2017); current status not publicly disclosed

Animal Health & Nutrition

ProductDescriptionStatus
TPM feed additiveImproves feed efficiency and livestock health (poultry and pig field trials historically)Minimal activity; not separately monitored [AR25 Note 4; AR23]

Financial Narrative

The FY2022–FY2025 line items come from the audited statements in [AR23] and [AR25]. FY2021 is limited to what is disclosed in the five-year tables and the opening balances in those reports. Avecho does not report EBITDA, operating income or ROIC as defined lines. These are derived as follows:

  • Operating income (EBIT) = loss before tax + finance costs.

  • EBITDA = EBIT + depreciation and amortisation (D&A from Note 4).

  • Interest income sits within "R&D tax incentive and other income" and is not stripped out.

Income statement (A$)

FY2021 line items other than revenue, net loss and EPS were not available in the sources reviewed.

Margins and growth (%)

Revenue CAGR FY2021–FY2025: about 11.8% a year (A$0.79M to A$1.24M).

Long view: FY2019 revenue was A$4.24M [AR23], so the 6-year trajectory is down.

Commentary — income statement. Revenue has swung with one dominant customer's ordering cycle:

  • FY2023 fell 58% "primarily due to a reduction in Vital ET® sales" [AR23].

  • FY2024 more than doubled.

  • H1 FY2026 collapsed to A$59.6k [HY26], so FY2026 revenue is likely to fall sharply unless second-half orders recover.

Gross margin is structurally high (60–72%) in normal years. FY2023 was negative because of inventory impairment.

The cost base has stepped up with the Phase III program:

  • R&D rose from A$1.59M (FY2022) to A$4.31M (FY2025), a 2.7x increase.

  • Clinical development expense alone rose from A$0.92M to A$3.48M [AR23 Note 7; AR25 Note 7].

  • The R&D tax incentive offsets about 46% of R&D spend (A$2.00M / A$4.31M in FY2025).

FY2025 finance costs jumped to A$461k, from A$57k. The FY2024 Endpoints facility accounts for only A$111,706 of interest [AR25 Note 13]; the rest likely reflects foreign-exchange losses on the USD-denominated Sandoz cash. Under the accounting policy, FX losses on borrowings sit in finance costs, and the A$3.9M USD exposure is disclosed in Note 18. This is our inference: the split is not explicitly disclosed.

Admin costs rose 27% in FY2025, driven by share-based payments (A$393,705 versus A$14,017), payroll and investor relations [AR25].

Balance sheet (A$, at 31 December)

FY2021 figures are the 1 Jan 2022 opening balances from [AR23]: cash from the cash-flow statement, and equity, issued capital and accumulated losses from the statement of changes in equity. Other FY2021 balance-sheet lines were not available in the sources reviewed.

Commentary — balance sheet. The balance sheet is very simple: cash plus the R&D refund receivable, against small payables and employee provisions, plus the Sandoz deferred revenue.

  • Accumulated losses of A$273.8M against issued capital of A$246.9M show how much capital the Phosphagenics/Avecho platform has absorbed over three decades.

  • FY2025 equity of A$1.56M understates economic net worth. The A$4.83M Sandoz contract liability is non-cash and will unwind into revenue rather than require cash repayment.

  • Unrecognised deferred tax assets total A$48.0M, including A$47.4M of tax losses at 25% [AR25 Note 9]. This latent asset is usable only if the company becomes profitable and passes continuity tests.

  • There are no goodwill or capitalised intangibles; all R&D is expensed.

Cash flow (A$)

FY2021 cash-flow detail was not available in the sources reviewed.

Commentary — cash flow. FY2025 is the only year of positive operating cash flow, and it is distorted. Customer receipts of A$6.49M include the ~A$4.79M Sandoz upfront. Excluding Sandoz, underlying operating cash burn was roughly A$3.7M, consistent with FY2024 (A$3.97M).

The steady-state burn is therefore about A$3.5–4.5M a year, partly offset by annual R&D refunds of A$1.7–2.0M received around May. That implies net funding needs of roughly A$2–2.5M a year before trial-completion and registration costs.

2026 liquidity events:

  • Cash was A$4.4M at 31 Mar 2026 [ASX 12 May 2026].

  • The company then received ~A$1.9M from option exercises and A$1.98M from the FY2025 R&D refund, of which A$1.62M repaid Endpoint Capital [ASX 22 May 2026].

  • Cash stood at A$6.6M at 30 Jun 2026 [Q2-26].

Ratios

Notes on the ratios:

  • ROA for FY2022 needs FY2021 total assets, which were not available.

  • ROIC is not meaningful: invested capital is negative or near zero excluding cash, and NOPAT is negative.

  • Net debt/EBITDA is not meaningful: the company has net cash and negative EBITDA.

  • Interest coverage is negative and shown only for completeness.

  • A cash conversion cycle is not meaningful given immaterial inventory and receivables; it is not disclosed.

  • The FY2025 ROE matches the Tiger aggregator figure of -182.91% [3P].

Ratio commentary. Standard profitability ratios carry little information for a pre-commercial biotech. The decision-relevant metrics are:

Runway: A$6.6M cash against a net burn of ~A$1–1.5M a quarter, implying about 4–6 quarters before Phase III completion costs rise.

Funding dependence: 100% reliance on equity, R&D refunds and licence payments.

Leverage: negligible. Debt is effectively limited to small leases and periodic R&D advances, which are self-liquidating against refunds.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment (AUD) and Segment Margins & Growth (%)

SegmentFY2022FY2023FY2024FY2025

Production revenue (AUD)

1,129,260473,5511,132,6721,237,762

Human Health revenue (AUD)

0000

Total revenue (AUD)

1,129,260473,5511,132,6721,237,762

Production % of total revenue

100100100100

Production revenue YoY growth (%)

42.3-58.1139.29.3

Revenue by Segment (AUD) and Segment Margins & Growth (%) — Production PBT

SegmentFY2022FY2023FY2024FY2025

Production PBT (AUD)

660,278-338,173459,997394,900

Human Health PBT (AUD)

-999,541-1,080,775-1,888,297-2,388,259

Corporate PBT (AUD)

-2,003,128-2,017,613-1,693,748-2,423,264

Group loss before tax (AUD)

-2,342,391-3,436,561-3,122,048-4,416,623

Production PBT margin (%)

58.5-71.440.631.9

Segment Assets & Liabilities (AUD)

ItemFY2022FY2023FY2024FY2025

Production segment assets (AUD)

1,231,542138,6301,067,0581,912,017

Human Health segment assets (AUD)

687,9271,076,2061,645,3721,982,754

Corporate segment assets (AUD)

1,426,0836,104,4742,284,3613,211,282

Human Health segment liabilities (AUD)

131,439213,413978,4434,964,201

Income Statement (AUD) and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (AUD)

793,6001,129,260473,5511,132,6721,237,762

Cost of sales (AUD)

—336,142517,346460,746349,386

Gross profit (AUD)

—793,118-43,795671,926888,376

R&D tax incentive and other income (AUD)

—727,8231,167,9841,893,7822,049,038

of which R&D tax incentive (AUD)

—622,9231,075,5671,635,4641,995,884

R&D expenses (AUD)

—1,593,8802,117,2633,591,1564,311,137

Administration and corporate expenses (AUD)

—2,263,1032,428,1312,039,4672,581,540

Finance costs (AUD)

—6,34915,35657,133461,360

Depreciation and amortisation (AUD)

—230,351178,695144,885137,089

Operating income / EBIT, derived (AUD)

—-2,336,042-3,421,205-3,064,915-3,955,263

EBITDA, derived (AUD)

—-2,105,691-3,242,510-2,920,030-3,818,174

Pre-tax income (AUD)

-3,416,116-2,342,391-3,436,561-3,122,048-4,416,623

Income tax expense (AUD)

—0000

Net income (AUD)

-3,416,116-2,342,391-3,436,561-3,122,048-4,416,623

EPS basic (A$ cents)

-0.19-0.13-0.15-0.10-0.14

EPS diluted (A$ cents)

-0.19-0.13-0.15-0.10-0.14

Dividends per share (A$ cents)

00000

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue growth YoY (%)

—42.3-58.1139.29.3

Gross margin (%)

—70.2-9.259.371.8

Operating (EBIT) margin (%)

—-206.9-722.5-270.6-319.6

EBITDA margin (%)

—-186.5-684.7-257.8-308.5

Net margin (%)

-430.5-207.4-725.7-275.6-356.8

Balance Sheet (AUD) and Share Count (millions)

MetricFY2021FY2022FY2023FY2024FY2025

Cash and cash equivalents (AUD)

3,264,7641,468,2105,504,3962,374,5344,663,491

Trade and other receivables (AUD)

—745,9941,099,5632,246,4612,204,549

Inventories (AUD)

—401,97997,117137,4598,066

Total current assets (AUD)

—2,851,1897,003,6424,810,2777,056,628

Total assets (AUD)

—3,345,5527,319,3104,996,7917,106,053

Short-term debt incl. current leases (AUD)

—70,92376,9261,062,19614,473

Long-term debt incl. non-current leases (AUD)

—175,15298,22514,4720

Total debt incl. leases (AUD)

—246,075175,1511,076,66814,473

Net debt, negative = net cash (AUD)

—-1,222,135-5,329,245-1,297,866-4,649,018

Contract liabilities (AUD)

—0158,37604,832,762

Total liabilities (AUD)

—920,656941,5401,727,0535,546,403

Total equity (AUD)

4,536,5902,424,8966,377,7703,269,7381,559,650

Goodwill and intangibles (AUD)

—26,250000

Working capital (AUD)

—2,105,6856,160,3273,099,8826,347,425

Issued capital (AUD)

237,601,871237,528,800244,605,505244,605,505246,901,334

Accumulated losses (AUD)

262,067,262264,104,330267,440,391269,391,751273,808,374

Shares on issue (millions)

1,836.11,837.93,169.33,169.33,673.5

NTA per share (A$ cents)

—0.130.200.100.04

Cash Flow (AUD)

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (AUD)

—-1,665,207-3,179,955-3,968,7181,103,098

Receipts from customers incl. GST (AUD)

—1,192,827758,215566,2346,491,167

R&D tax incentive and EMDG receipts (AUD)

—1,039,938723,8881,066,2981,695,102

Capital expenditure (AUD)

—53,124000

Free cash flow (AUD)

—-1,718,331-3,179,955-3,968,7181,103,098

Proceeds from share issues, gross (AUD)

—1,9898,003,59402,500,000

Borrowings received / (repaid) net (AUD)

—00931,512-1,043,218

Net cash from financing (AUD)

—-78,2237,216,141854,5861,185,859

Dividends paid (AUD)

00000

Share buybacks (AUD)

00000

Net change in cash (AUD)

—-1,796,5544,036,186-3,129,8622,288,957

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE, average equity (%)

-67.3-78.1-64.7-182.9

ROA, average assets (%)

—-64.4-50.7-73.0

Current ratio (x)

3.828.312.819.95

Debt / equity incl. leases (x)

0.100.030.330.01

Interest coverage, EBIT / finance costs (x)

-367.9-222.8-53.6-8.6

Asset turnover, revenue / average assets (x)

—0.090.180.20

R&D tax incentive / R&D expense (%)

39.150.845.546.3

Revenue by Region (AUD)

Region / countryFY2022FY2023FY2024FY2025

Australia (AUD)

24,55038,30738,167136,983

Switzerland (AUD)

1,009,945403,444352,6221,068,532

Americas incl. United States (AUD)

69,2630708,5400

India (AUD)

25,50231,80033,34322,500

France (AUD)

0009,747

Total (AUD)

1,129,260473,5511,132,6721,237,762

Revenue by Region (%)

RegionFY2022FY2023FY2024FY2025

APAC, Australia plus India (%)

4.414.86.312.9

EMEA, Switzerland plus France (%)

89.485.231.187.1

Americas (%)

6.10.062.60.0

Revenue by Region (%) (FY2023–FY2025)

RegionFY2023FY2024FY2025

Australia (%)

56.0-0.4258.9

Switzerland (%)

-60.1-12.6203.0

India (%)

24.74.9-32.5

Per-Share Data and Share Count (millions)

MetricFY2021FY2022FY2023FY2024FY2025

Share price at year end (A$ cents)

1.501.500.350.250.90

Shares on issue at year end (millions)

1,836.11,837.93,169.33,169.33,673.5

Market cap at year end, derived (AUD Mn)

27.527.611.17.933.1

Valuation Snapshot

MetricValueSource

Recent price

A$0.018–0.020 (late Sep / early Oct 2026)

[3P: Tiger; InvestSMART]

52-week range

A$0.003 – A$0.027

[3P: Tiger]

Market cap

About A$69–77M

[3P]

Enterprise value (market cap less A$6.6M cash)

About A$62–70M

Derived

1-year performance

Roughly +280% to +390% (from ~A$0.004–0.005 in Oct 2025); Market Index cites +386% relative to the ASX 200 over 1 year

[3P: Market Index; ASX 23 Oct 2025 placement pricing]

3-year performance

Roughly +200% to +400% (from ~A$0.004–0.006 in late 2023)

Derived from placement and year-end prices; approximate

5-year performance

Roughly +20% to +30% (from ~1.5c at end-2021)

Derived; approximate

Valuation Multiples

MultipleAvechoComment

P/E

Not meaningful (loss-making; Tiger shows -12.9x LYR)

[3P]

EV/EBITDA

Not meaningful (negative EBITDA)

—

EV/Sales (TTM revenue ~A$0.74M)

About 85–95x

TTM = FY2025 − H1 FY2025 + H1 FY2026

P/B

About 44x

[3P: Tiger 44.21]

Analyst Conclusions

Management guidance. There is no financial guidance. Operational guidance is to:

  • complete recruitment and dosing of the second cohort (recruitment restarted 31 Aug 2026, with additional sites);

  • reach the final analysis;

  • lodge a TGA submission as soon as possible after a positive result, supported by registration batches already under way;

  • progress ex-Australia licensing and FDA/EU regulatory engagement.

Consensus. None available.

Bull case

  1. The interim pass is genuinely informative. The DMB required no increase in sample size, which the company says shows the treatment effect and variability are tracking the trial's design assumptions. This raises the probability of final success above typical Phase III base rates.

  2. The economics are asymmetric. Up to US$16M in Sandoz milestones, 14–19% royalties plus supply margin in Australia, and fully retained rest-of-world rights could each be worth more than the current EV of about A$65M if the final data are positive. The new BD capability and the post-interim momentum improve the odds of a second licence.

  3. Funding risk is lower than history suggests. With A$6.6M cash, annual R&D refunds of about A$2M, no debt and the option overhang gone, the company can probably reach the final readout with modest or no further dilution, particularly if a licence deal brings upfront cash.

Bear case

  1. CBD has a poor sleep-trial record and Avecho is still blinded. A "continue" recommendation does not confirm efficacy, and peers' Phase III CBD sleep studies failed. A final miss would leave only a sub-A$1.5M ingredient business.

  2. Regulatory and commercial novelty. The TGA has never registered a CBD pharmaceutical. Schedule 3 pricing, pharmacist uptake and competition from melatonin and other sleep aids are unproven, and the US$125M market estimate is the company's own.

  3. Thin margin for error. The share price has risen roughly 4x in a year (P/B about 44x; EV/Sales about 90x on collapsing ingredient revenue). Going-concern language, 97% customer concentration and a history of deep-discount raises point to downside if timelines slip again; the interim itself arrived about 18 months late.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhy it matters
September 2026 quarterly 4CBy 31 Oct 2026Cash runway and recruitment rate for the second cohort
Recruitment completion and last-patient-last-doseH2 2026 – 2027 (not specified)Sets the timing of the final readout
Ex-Australia licensing deal(s)Any time; BD hire Aug 2026Non-dilutive cash; tests whether Sandoz exercises its ROFR
FDA / EU regulatory feedbackPost-interimDefines the size of global opportunity
FY2026 R&D tax refundAbout May 2027About A$1.5–2.0M of funding
FY2026 annual reportLate Feb 2027Going-concern status; Sandoz revenue recognition
Final Phase III top-lineAfter completion (not dated)Binary value event
TGA submissionAfter positive top-lineTriggers Sandoz development milestones
Board renewal2026–2027Restore a fourth director and committee structure
Ingredient orders (Vital ET®)H2 2026Whether H1 FY2026 weakness was timing or structural

Analyst verdict

Avecho has become a single-asset, event-driven biotech. Its investment case rests almost entirely on whether a TPM-enhanced CBD capsule can show statistically robust efficacy in insomnia in a 519-patient pivotal trial. The June 2026 interim analysis materially changed the risk profile. An independent DMB saw unblinded data from 244 patients and recommended continuing without enlarging the study, with no serious adverse events. In adaptive designs, a weak or noisy signal usually triggers a sample-size increase, so this outcome is meaningfully positive. It is still not proof of efficacy, and investors should resist treating it as such, especially given CBD's record of failed sleep trials.

Commercially, the Sandoz agreement gives unusual validation for a company of Avecho's size. Its royalty band of 14–19%, plus supply margin and US$16M in milestones, is attractive, and rest-of-world rights remain unencumbered apart from Sandoz's ROFR. The balance sheet is more stable than at any point since 2023: A$6.6M cash, no debt, the AVEOA overhang removed and dependable R&D refunds. Governance and operations are thin, though. The board has three directors and no committees, revenue depends on one customer, and the ingredient business that once anchored the company has shrunk to near-irrelevance in H1 FY2026.

At about A$65–70M EV, the market is already pricing a reasonable chance of success after a roughly fourfold re-rating. On our assessment, the risk-reward is now balanced to modestly positive for investors who can tolerate binary outcomes. The upside depends on confirmatory top-line data, an ex-Australia licence, and a clear TGA path to the first Schedule 3 CBD registration. The downside is a final-readout miss, which would likely erase most of the value. We would track the quarterly recruitment cadence, cash burn and any licensing announcement as the leading indicators.

All figures are from public filings and reputable aggregators as cited. Nothing here constitutes investment advice.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / backgroundBase salary (31 Dec 2025, incl. super)

Dr Paul Gavin, BSc (Hons), PhD

Chief Executive Officer

CEO since 1 May 2020; previously Chief Scientific Officer

Long-standing Avecho/Phosphagenics scientist and TPM technology lead

A$380,000; 6-month notice [AR25]

Dr Roksan Libinaki, PhD

Chief Operating Officer

KMP throughout FY2022–FY2025

Long-serving Avecho scientific and operations executive

A$280,000; 3-month notice [AR25]

Naomi Lawrie

Company Secretary

Appointed Jun quarter 2026, replacing Melanie Leydin (Vistra)

Company secretarial professional

—

Eve Williamson

Strategic Business Development Consultant (not KMP)

Appointed 24 Aug 2026

Senior pharmaceutical executive with portfolio strategy and commercial leadership experience

—

“—” = not publicly disclosed.

Board of Directors

NameRoleAppointedBackgroundIndependenceOther listed boards

Dr Gregory Collier, PhD

Non-Executive Chairman

Chair since at least 2017 [3P: Biotech Daily]

25+ years in pharma R&D and commercialisation. Former CEO of ChemGenex (sold to Cephalon for A$230M in 2011). Inaugural Alfred Deakin Professor; 150+ publications; 33 patents; Roche Award of Excellence 2010

Independent NED

—

Dr Ross Murdoch, BSc (Hons), PhD, GAICD

Non-Executive Director

Director since Apr 2015

Former Avecho CEO (Jan 2015 – Mar 2019); ex-SVP Shire (USA/Switzerland); ex-President and COO of Prana Biotechnology

Non-executive. Not independent under the ASX three-year look-back until 2022; now arguably independent

—

Ms Kathy Connell, GAICD

Non-Executive Director

c.Apr 2024

Former BD, licensing and external-innovation lead at J&J and Sanofi in ANZ (over US$1B deployed); Korn Ferry; registered psychologist; co-founder of Medicines Australia's PAIG; BioMelbourne Woman of the Year 2018

Independent NED

Opthea Ltd (ASX/NASDAQ: OPT); also Proto Axiom, BioNSW

Mr Matthew McNamara, BSc (Hons), MBA, GAICD

Former Non-Executive Director

13 Jan 2020 – resigned Jun quarter 2026

CIO of Horizon 3 Healthcare, which invested in Avecho through trustee Melbourne Securities Corporation [AR23]

Was nominee-linked

—

Directors' Remuneration

NameSalary / feesLeave accrualsBonus (shares)SuperannuationLong service leaveOptions (share-based)Total FY2025Total FY2024

Gregory Collier

100,000000016,194116,194100,000

Ross Murdoch

50,032005,87808,09764,00755,263

Matthew McNamara

50,032005,87808,09764,00755,263

Kathy Connell

50,032005,878012,43868,34846,053

Paul Gavin (CEO)

362,50017,10812,50041,12555,378161,940650,551256,823

Roksan Libinaki (COO)

262,500-13,19712,50029,375-61180,970371,537302,323

Total

875,0963,91125,00088,13454,767287,7361,334,644815,725

Board & Management Changes

DateChangeContext

c.Apr 2024

Kathy Connell joins board

Adds global licensing and BD expertise before the out-licensing push

Jun quarter 2026

Matthew McNamara resigns

Removes the Horizon 3 Healthcare-linked director; board falls to three [Q2-26]

Jun quarter 2026

Naomi Lawrie replaces Melanie Leydin as Company Secretary

Administrative [Q2-26]

24 Aug 2026

Eve Williamson engaged as senior BD consultant

Builds out-licensing capability after the positive interim result [ASX 24 Aug 2026]

Major Shareholders

HolderSharesStakeDateSource

Mark Gregory Kerr and associates (incl. Linda Kerr)

349,133,1889.50%

Notice dated 18 Feb 2026 (dilution-driven; previously 11.00% at 19 Jun 2025 and 11.02% at 12 Feb 2024)

[3P: Market Index; InvestSMART; TipRanks]

Major Shareholders by Rank

RankHolderSharesApprox. stake
1

Chunyan Niu

252,000,0006.9%
2

Mark Kerr

174,566,5944.8%
3

Linda Kerr

174,566,5944.8%
4

Melbourne Securities Corporation Ltd (trustee for Horizon 3 Healthcare)

101,012,2902.8%
5

Rosscope Pty Ltd

85,513,1292.3%
6

Wayne Kent

50,000,0001.4%
7

Servbond Pty Ltd

47,000,0001.3%
8

Brandon Batagol

44,532,4061.2%
9

10 Bolivianos Pty Ltd

43,796,3591.2%
10

Sked Proprietary Ltd

42,000,0001.1%

Shareholding Trend

HolderShares at 31 Dec 2025Options at 31 Dec 2025

Gregory Collier

9,833,33318,088,594

Ross Murdoch

3,333,3335,669,297

Matthew McNamara

1,666,6665,669,297

Paul Gavin

15,517,50765,885,940

Roksan Libinaki

14,333,33232,235,308

Kathy Connell

07,162,942

Total

44,684,171 (≈1.2%)

134,711,378

Competitive Landscape

Key Competitors

#CompetitorSegmentPositioning versus AvechoRevenue / scale
1

Jazz Pharmaceuticals (Epidiolex)

Prescription CBD (epilepsy)

Only major regulator-approved CBD drug; not approved for insomnia; validates pharmaceutical-grade CBD

Very large (multi-billion US$); Epidiolex roughly US$1B a year.

2

Bod Science Ltd (ASX: BOD)

Australian CBD / medicinal cannabis; Schedule 3 ambitions

Australian peer pursuing CBD medicines; named alongside Avecho as a comparable [3P: GlobalData]

—
3

Little Green Pharma (ASX: LGP)

Australian medicinal cannabis producer

Prescription-channel cannabis supplier; potential low-dose CBD entrant

—
4

Botanix Pharmaceuticals (ASX: BOT)

Dermatology (historically topical synthetic CBD)

Former cannabinoid peer, now pivoted; listed as a GlobalData comparable

—
5

Zelira Therapeutics

Cannabinoid insomnia formulations

Direct cannabinoid-for-insomnia competitor

—
6

Other Australian Schedule 3 CBD aspirants (various)

OTC CBD

Avecho states that no other Phase III CBD insomnia program is positioned for Schedule 3 registration [ASX 31 Aug 2026]; peers' Phase III sleep studies missed significance [3P: SmallCaps 2023]

—
7

Merck & Co (Belsomra, suvorexant)

Rx insomnia (orexin antagonist)

Established Rx therapy; Avecho targets an OTC, tolerability-led niche

—
8

Eisai (Dayvigo, lemborexant)

Rx insomnia

As above

—
9

Idorsia (Quviviq, daridorexant)

Rx insomnia

As above

—
10

Neurim / generic melatonin (Circadin)

Rx/OTC sleep aids in Australia

Incumbent pharmacy sleep products in Australia; key OTC substitute

—
11

Generic hypnotics (zolpidem, temazepam)

Rx insomnia

Low-cost incumbents with dependence and next-day-effect concerns, which supports CBD's tolerability positioning

—
12

Catalent / Lonza and other solubility-enhancement CDMOs

Drug-delivery platforms

Larger platform providers competing for formulation partnerships

Very large; not relevant at Avecho scale

Competitor Detail

MetricAvecho (FY2025)

Revenue

A$1.24M

Revenue growth

+9.3%

Gross margin

71.8%

Net margin

-356.8%

R&D intensity (R&D / revenue)

348%

Late-stage CBD insomnia asset

Yes (Phase III, positive interim)

Recent Developments

There have been no layoffs, litigation or regulatory actions in the period. The September 2026 quarterly (Appendix 4C) is due by 31 October 2026 and had not been released at the dossier date.

Company Snapshot

15

Employees

1992

Founded

Clayton, Australia

Headquarters

SWOT Analysis

Strengths

  • Pivotal trial de-risked at interim: DMB unanimously recommended continuing to 519 participants with no sample-size increase (24 Jun 2026)
  • Clean safety signal: No serious adverse events across 244 participants at interim [ASX 24 Jun 2026]
  • Big-pharma validation and economics: Sandoz deal: US$3M upfront, up to US$16M milestones, 14–19% royalties, plus product supply margin [AR25]
  • Durable core IP: US TPM manufacturing-process patent to at least Dec 2037; granted in India, Japan, Mexico, Russia and Singapore [AR23]
  • Experienced board for deal-making: Chair Collier sold ChemGenex to Cephalon for A$230M; Connell led over US$1B of J&J/Sanofi external innovation in ANZ [AR25]
  • Low fixed-cost, capital-light model: About 15 staff; capex nil in FY2023–FY2025; outsourced CMOs [AR25; 3P]
  • Profitable ingredient niche: Production segment PBT of A$394,900 in FY2025 (31.9% margin) [AR25]

Weaknesses

  • Going-concern material uncertainty: Disclosed in FY2023 and FY2025 accounts [AR23; AR25]
  • Extreme customer concentration: About 97% of Production revenue from one customer group in FY2025 [AR25]
  • Volatile, shrinking revenue: H1 FY2026 revenue of A$59.6k vs A$560.1k [HY26]; FY2019 revenue was A$4.24M [AR23]
  • Thin book equity: Net assets A$1.56M; NTA 0.04c per share (FY2025) [AR25]
  • Heavy historical dilution: Shares rose from 1.84B (FY2022) to about 3.85B (2026); A$273.8M accumulated losses [AR25; 3P]
  • Minimal governance infrastructure: Three-person board after McNamara's resignation; no separate audit or remuneration committees [AR25; Q2-26]
  • Recruitment has been slow: Interim originally expected end-2024 [AR23]; achieved Jun 2026

Opportunities

  • First-mover in Australian Schedule 3 CBD: Market forecast above US$125M a year [ASX 2 Mar 2026]
  • Ex-Australia licensing: Active multi-jurisdiction discussions; dedicated BD hire Aug 2026 [AR25; ASX 24 Aug 2026]
  • Milestone cash: Up to US$16M development milestones from Sandoz before commercial sales [AR25]
  • FDA and EU pathway: Planned engagement with FDA and European regulators after the interim [3P: Sleep Review]
  • Platform extension: Gummies, oils and topical cannabinoids; Perrigo ibuprofen gel; Arthur Group oncology [AR23]
  • Latent tax shield: A$47.4M of unrecognised tax-loss DTAs [AR25 Note 9]

Threats

  • Final efficacy failure: Peers' Phase III CBD sleep studies failed to separate from placebo [3P: SmallCaps 2023]; Avecho remains blinded
  • Regulatory novelty: The TGA has not assessed a CBD pharmaceutical submission, and no agency has approved CBD for insomnia [3P: BioMelbourne 2023]
  • Funding and dilution: Annual net burn of about A$2–4M versus A$6.6M cash; history of deep-discount raises (A$0.005–0.006) [AR25; Q2-26]
  • R&D tax incentive policy risk: Refunds of A$1.7–2.0M a year are central to funding [AR25 risk factors]
  • Partner leverage: Sandoz ROFR may deter or reprice other bidders; dependence on CMOs [AR25]
  • Competitive fast followers: Other CBD sponsors could pursue Schedule 3 once the evidence standard is set; incumbent OTC sleep aids such as melatonin

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
28 Mar 2025Receipt of US$3M (~A$4.79M) Sandoz upfront [AR25]Largest non-dilutive inflow in years
16 Apr 20254.17M shares issued to CEO and COO for 2024 KPIs (A$0.006) [AR25]STI settlement
27 May 2025AGM; remuneration report passed with 98.34% [AR25]Governance
27 May 2025142.6M EIP options issued (A$0.0066, expiring Nov 2028) [AR25]LTI alignment; about 3.9% dilution
28 May 2025FY2024 R&D refund of A$1.7M received; Endpoints advance (A$931,512 principal) repaid [AR25]Liquidity
19 Jun 2025Kerr substantial-holder notice: 11.52% to 11.00% (inter-account transfer) [3P: TipRanks]Register stability
Aug 2025H1 FY2025 results: revenue A$560.1k (+79%); net loss A$2.68m [3P: Simply Wall St]Ingredient sales strong in H1
23 Oct 2025A$2.5M placement announced at A$0.005 (20.6% discount to 15-day VWAP) [ASX 23 Oct 2025]Funds commercial manufacturing
3 Nov 2025500M placement shares and 20M options (A$0.012, expiring May 2026) issued [AR25]Completion
Late 2025190 patients dosed of ~210 needed for interim [AR25]Recruitment progress
Feb 2026Independent DMB begins work [ASX 26 May 2026]Interim governance
18 Feb 2026Kerr holding diluted to 9.50% [3P: Market Index]Register
27 Feb 2026FY2025 annual report: revenue A$1.24M (+9.3%); loss A$4.42M (+41.5%); going-concern material uncertainty disclosed [AR25]Audited results
2 Mar 2026Interim-analysis cohort recruitment completed; interim guided for Jun 2026 [ASX 2 Mar 2026]Milestone
Q1 2026New Endpoint Capital R&D advance against FY2025 refund (repaid A$1.62M in May) [ASX 22 May 2026]Bridge financing
29 Apr 2026Notice of AVEOA listed option expiry sent to holders [ASX 29 Apr 2026]Capital
10–12 May 2026AVEOA options (2.167B on issue at 30 Apr) expire; ~A$1.9M exercised [ASX 12 May 2026]Overhang removed; cash added
21 May 2026Treatment complete for 244-participant interim cohort [ASX 21 May 2026]Milestone
22 May 2026FY2025 R&D refund of A$1.98M received; A$1.62M repaid to Endpoint Capital [ASX 22 May 2026]Liquidity
25 May 2026CEO investor webinar [ASX 21 May 2026]Investor relations
26 May 20262026 AGM held at Grant Thornton, Collins Square; results lodged [ASX 26 May 2026]Governance
22 Jun 2026Trading halt pending interim analysis outcome [ASX 22 Jun 2026]Disclosure
24 Jun 2026Positive interim analysis: DMB unanimously recommends continuing to 519 participants with no sample-size increase and no SAEs among 244 participants [ASX 24 Jun 2026]Key de-risking event; shares re-rated
29 Jun 2026PR Newswire international release of interim result [3P: PR Newswire via Webull]Global BD visibility
Jun quarter 2026Matthew McNamara resigns as NED; Naomi Lawrie appointed Company Secretary [Q2-26]Governance
29 Jul 2026June quarterly 4C: cash A$6.6M at 30 Jun 2026 [Q2-26]Liquidity
24 Aug 2026Eve Williamson appointed senior BD consultant [ASX 24 Aug 2026]Licensing push
26 Aug 2026H1 FY2026: revenue A$59.6k (vs A$560.1k); loss A$1.92M (vs A$2.68M); R&D A$1.82M [HY26]Ingredient revenue collapse; lower loss
31 Aug 2026Recruitment restarts for final stage of Phase III [ASX 31 Aug 2026]Trial execution
23 Sep 2026Presentation at ASX SMIDcaps Conference [ASX 23 Sep 2026]Investor relations

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement (AUD): Revenue to Administration and corporate expenses: Revenue rose from AUD 793,600 in FY2021 to AUD 1,237,762 in FY2025.
Avecho Biotechnology Limited — Income Statement (AUD): Revenue to Administration and corporate expenses
Series (AUD)FY2021FY2022FY2023FY2024FY2025
Revenue793,6001,129,260473,5511,132,6721,237,762
Cost of sales—336,142517,346460,746349,386
Gross profit—793,118-43,795671,926888,376
R&D tax incentive and other income—727,8231,167,9841,893,7822,049,038
of which R&D tax incentive—622,9231,075,5671,635,4641,995,884
R&D expenses—1,593,8802,117,2633,591,1564,311,137
Administration and corporate expenses—2,263,1032,428,1312,039,4672,581,540

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.